Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India

描述(申请人提供)：在全球范围内，印度是全球艾滋病毒感染者最多的国家之一，估计有240万人。恶性肿瘤是已知的艾滋病毒感染的并存疾病，在世界许多地区呈上升趋势。印度艾滋病毒感染者的癌症发病率和表现尚未得到很好的描述，未诊断的艾滋病毒感染患者中可能以癌症为其艾滋病毒感染的第一个症状的比例尚不清楚。这项提案的目标是获得印度北部一家主要癌症治疗和转诊中心在1-2年期间看到的癌症人口中艾滋病毒流行率的信息。我们同样会评估前往同一机构(例如乳癌、子宫颈癌和前列腺癌)癌症筛查诊所就诊的患者的艾滋病毒感染率。另一个目标是收集信息；人口统计、艾滋病毒和介绍时的临床状况、艾滋病毒和癌症风险因素，以及关于艾滋病毒携带者和癌症患者的癌症发病率、癌症类型、阶段、治疗和治疗结果的信息。此外，我们将类似地评估各种癌症风险因素和各种致癌病毒在癌症患者中的流行率(与在本研究时间框架内来自同一机构的同一艾滋病毒诊所的同时控制的未患癌症的艾滋病毒患者相比)。这将有助于评估各类癌症中艾滋病毒的流行情况，并提供有关短期癌症事件以及艾滋病毒感染者癌症发展的各种风险因素和辅助因素的信息。这项研究中确诊的癌症和艾滋病毒患者将在癌症和艾滋病毒登记中登记 和标本/组织库，我们将帮助建立标本/组织库，用于未来的后续行动和标本收集，以获得关于癌症和艾滋病毒治疗和临床结果的数据，并为未来的研究研究提供队列，包括流行病学、实验室和可能的临床试验。用采集的肿瘤和血液样本建立艾滋病毒和癌症登记将为我们的印度研究人员同事提供进一步研究的宝贵资源(未来印度将提供额外的外部资金)。这项研究将涉及加州大学洛杉矶分校、新德里全印度医学科学研究所(AIIMS)的研究人员和AIIMS的B.R.Ambedkar研究所和扶轮癌症医院(Dr BRAIRCH)的研究人员之间的合作。总体目标是更好地描述印度艾滋病毒和癌症的重要联系，并确定 风险因素和潜在的病毒辅助因素，最终可能成为未来对艾滋病毒这一重要共同发病的治疗和预防干预措施的基础。

DESCRIPTION (provided by applicant): Globally, India has one of the largest populations of HIV-infected people, estimated at 2.40 million individuals. Malignancy is a known co-morbidity of HIV infection and is growing in proportion in many parts of the world. The incidence and manifestations of cancer in HIV-infected individuals in India has not yet been well characterized, and the proportion of patients with undiagnosed HIV infection who may be presenting with cancer as their first manifestation of HIV infection is not known. The goal of this proposal is to obtain information on the prevalence of HIV in the cancer population seen over a 1-2 year period at a major cancer treatment and referral center in Northern India. We will similarly assess the HIV prevalence of patients presenting to cancer screening clinics at the same institution (e.g. breast, cervical and prostate). Another goal is to collect information; demographics, HIV and clinical status at presentation, HIV and cancer risk factors, as well as information on incidence of cancer, cancer types, stage, treatments and treatment outcomes in patients with HIV and cancer. In addition we will similarly assess various cancer risk factors and the prevalence of various oncogenic viruses in patients with incident cancers (compared to concurrent control HIV+ individuals from the same HIV clinic at the same institution that do not develop cancer in the timeframe of this study. This will allow assessment of HIV prevalence in various cancers types as well as provide information on the short- term cancer incident and various risk factors and co-factors for cancer development among HIV-infected persons. Identified cancer and HIV individuals from this study will be enrolled in a cancer and HIV registry and specimen/tissue bank, which we will help establish, for prospective follow-up and specimen collection to obtain data on cancer and HIV treatments and clinical outcomes and to provide a cohort for future research studies, including epidemiologic, laboratory and possible clinical trial. Establishment of the HIV and cancer registry with collected tumor and blood specimens will provide our Indian investigator colleagues with a valuable resource for further research (with additional future Indian outside funding). This study will involve a collaboration between investigators at UCLA, the All India Institute for Medical Sciences (AIIMS) in New Delhi and the Dr. B.R. Ambedkar Institute and Rotary Cancer Hospital (DR BRAIRCH) at AIIMS The overall goal is to better characterize the important association of HIV and cancer in India and to identify risk factors and potential viral co-factors which may ultimately service as the basis for future therapeutic and prevention interventions for this important co-morbidity in HIV.